These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38040765)

  • 1. Comparative effectiveness of first-line antihypertensive drug classes on the maintenance of estimated glomerular filtration rate (eGFR) in real world primary care.
    Gao Q; Tan NC; Lee ML; Hsu W; Choo J
    Sci Rep; 2023 Dec; 13(1):21225. PubMed ID: 38040765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
    Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2020; 40(1):38-45. PubMed ID: 31196659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.
    Pongpanich P; Pitakpaiboonkul P; Takkavatakarn K; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
    Int Urol Nephrol; 2018 Dec; 50(12):2261-2278. PubMed ID: 30324578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality.
    Faucon AL; Fu EL; Stengel B; Mazhar F; Evans M; Carrero JJ
    Kidney Int; 2023 Sep; 104(3):542-551. PubMed ID: 37330214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term comparative effectiveness of antihypertensive monotherapies in primary prevention of cardiovascular events: a population-based retrospective inception cohort study in the Netherlands.
    Li X; Bijlsma MJ; Bos JHJ; Schuiling-Veninga CCM; Hak E
    BMJ Open; 2023 Aug; 13(8):e068721. PubMed ID: 37558444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
    Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
    Suchard MA; Schuemie MJ; Krumholz HM; You SC; Chen R; Pratt N; Reich CG; Duke J; Madigan D; Hripcsak G; Ryan PB
    Lancet; 2019 Nov; 394(10211):1816-1826. PubMed ID: 31668726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diuretics versus others for long-term clinical outcomes as first-line antihypertensive medications: analysis of national real-world database.
    Kim HL; Hwang D; Lee JH; Lee HY; Ihm SH; Kim KI; Shin J; Park S; Kim DH; Sung KC
    Hypertens Res; 2022 May; 45(5):758-768. PubMed ID: 35338336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of antihypertensive treatment using real-world Japanese data-the retrospective study of antihypertensives for lowering blood pressure (REAL) study.
    Ohishi M; Yoshida T; Oh A; Hiroi S; Takeshima T; Otsuka Y; Iwasaki K; Shimasaki Y
    Hypertens Res; 2019 Jul; 42(7):1057-1067. PubMed ID: 30842611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
    Ku E; McCulloch CE; Vittinghoff E; Lin F; Johansen KL
    J Am Heart Assoc; 2018 Oct; 7(19):e009992. PubMed ID: 30371331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization patterns of antihypertensive drugs among the chronic kidney disease population in the United States: a cross-sectional analysis of the national health and nutrition examination survey.
    Sonawane KB; Qian J; Hansen RA
    Clin Ther; 2015 Jan; 37(1):188-96. PubMed ID: 25524390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.
    Bhandari S; Mehta S; Khwaja A; Cleland JGF; Ives N; Brettell E; Chadburn M; Cockwell P;
    N Engl J Med; 2022 Dec; 387(22):2021-2032. PubMed ID: 36326117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States.
    LaVallee C; Rascati KL; Gums TH
    J Clin Hypertens (Greenwich); 2020 Nov; 22(11):2084-2092. PubMed ID: 32951318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study.
    Rouette J; McDonald EG; Schuster T; Brophy JM; Azoulay L
    BMJ Open; 2022 Jun; 12(6):e057510. PubMed ID: 35688595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actual impact of angiotensin II receptor blocker or calcium channel blocker monotherapy on renal function in real-world patients.
    Satoh M; Hirose T; Satoh H; Nakayama S; Obara T; Murakami T; Muroya T; Asayama K; Kikuya M; Mori T; Imai Y; Ohkubo T; Metoki H
    J Hypertens; 2022 Aug; 40(8):1564-1576. PubMed ID: 35792108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis.
    Lin YC; Lin JW; Wu MS; Chen KC; Peng CC; Kang YN
    PLoS One; 2017; 12(12):e0188975. PubMed ID: 29240784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.